Trials / Completed
CompletedNCT05718375
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel Phase IIb Clinical Trial for the Efficacy Assessment and Safety Evaluation by Treating CU01-1001 for 24 Weeks in Type 2 Diabetic Nephropathy Patients With Albuminuria
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Curacle Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CU01-1001 | CU01-1001 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-02-14
- Primary completion
- 2025-11-12
- Completion
- 2025-11-12
- First posted
- 2023-02-08
- Last updated
- 2026-03-27
Locations
24 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05718375. Inclusion in this directory is not an endorsement.